Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/95797
Type: Artigo de periódico
Title: Recently Diagnosed Epilepsies: Adherence, Tolerance And Prognosis Of The First Epileptic Drug [epilepsias Recem-diagnosticadas: Aderencia, Tolerancia E Prognostico Com A Primeira Droga]
Author: Guerreiro C.A.M.
Voetsch B.
Montenegro M.A.
Silveira D.C.
Costa A.L.C.
Cardoso T.A.M.
Silva E.A.
Guerreiro M.M.
Abstract: There are few data related to recently diagnosed epilepsy (RDE) in Brazil. We followed up 78 patients ages ranging from 6 to 61 years (average 17.96) with RDE for 12.68 months (1-29 months) aiming to evaluate adherence, tolerance and efficacy of the first epileptic drug used. All patients had partial seizures with or without secondarily generalized and tonic-clonic seizures for an average of 7.68 months (4 days to 7 years). We found 11 patients (14.10%) not adherent to the treatment and 14 (17.94%) with side-effects that provoked the drug substitution. The most prevalent side-effects were dysmorphic signs such as hirsutism and gingival hyperplasia, gastro-intestinal symptoms, idiosyncratic reations and sedation. Sixty-six per cent of the patients were seizure-free after 8 weeks and 63.8% for 56 weeks of treatment. These data are consistent with the international literature. The ratio of non-adherent to the treatment was high (14.10%), probably due to socio-economic and cultural aspects of the studied population. We stressed that 17.94% of the patients do not tolerate the first antiepileptic drug, requiring substitution. Approximately 2/3 of the patients with RDE obtained good results with the first medication.
Editor: 
Rights: fechado
Identifier DOI: 
Address: http://www.scopus.com/inward/record.url?eid=2-s2.0-0028901630&partnerID=40&md5=d40ad3e468754f25607867b929a359da
Date Issue: 1995
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.